Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection

This publication has 13 references indexed in Scilit:

• Evidence That Tacrolimus Augments the Bioavailability of Mycophenolate Mofetil Through the Inhibition of Mycophenolic Acid Glucuronidation
  Therapeutic Drug Monitoring, 1999
• Comparison of long-term effects between tacrolimus and cyclosporine based immunosuppression after HTx: B.M. Meiser, D. Schmidt, M. Pfeiffer*, W.v. Scheidt**, V. Klauss***, S. Wildhirt, P.U¨berfuhr, H. Reichenspurner, B. Reichart; Depts. of Cardiac Surgery and Internal Medicine**, Institute for Clinical Chemistry*, Univ. of Munich, Groβhadern Medical Center and Dept. of Int. Med., Innenstadt Med. Center***, 81366 Munich, Germany
  The Journal of Heart and Lung Transplantation, 1999
• Medium-Term Outcome of Tacrolimus Immunosuppression Following Rejection or Graft Dysfunction in Heart Transplant Patients
  Transplantation Proceedings, 1998
• TACROLIMUS AS A RESCUE IMMUNOSUPPRESSANT AFTER HEART AND LUNG TRANSPLANTATION1
  Transplantation, 1998
• Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings
  Transplant Immunology, 1997
• A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: Intermediate-term results
  The Journal of Thoracic and Cardiovascular Surgery, 1996
• A PROSPECTIVE RANDOMIZED TRIAL OF FK506 VERSUS CYCLOSPORINE AFTER HUMAN PULMONARY TRANSPLANTATION1
  Transplantation, 1994
• Clinical trial of FK 506 immunosuppression in adult cardiac transplantation
  The Annals of Thoracic Surgery, 1992
• PRELIMINARY EXPERIENCE WITH FK506 IN THORACIC TRANSPLANTATION
  Transplantation, 1991
• FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATION
  The Lancet, 1989